Aquestive Therapeutics to Host Investor & Analyst Libervant (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting

WARREN, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that it will host an investor & analyst update forum related to the Company’s therapeutic candidate Libervant (diazepam) Buccal Film on Monday, December 9 from 4 pm to 5:30 pm ET at the American Epilepsy Society (AES) 2019 Annual Meeting in Baltimore.

Key opinion leaders and Aquestive’s management will provide a summary of the data from the five posters that will be presented at AES.  Aquestive has recently completed its rolling submission of a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for Libervant.

The event is intended for institutional investors and sell-side analysts.  Please RSVP in advance by contacting Stephanie Carrington at [e-mail] if you plan to attend, as space is limited.  A live webcast and replay of the presentations will be accessible from the "Events and Presentations" page in the Investors section of the Company's website (Link).  Investors and analysts may also listen to the live event via conference call by dialing [phone] from the U.S. and [phone] internationally, followed by the conference ID: 7450477.

About Libervant
Libervant is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy which, as a rectal gel, is invasive, inconvenient, and difficult to administer. As a result, a large portion of the patient population does not receive adequate treatment or foregoes treatment altogether. It is anticipated that, once approved, Libervant will enable a larger share of these patients to receive more appropriate treatment by providing consistent therapeutic dosing in a non-invasive and innovative treatment form.